We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Cardiovascular · CPC catalog code UROT-001
This sequence carries terminal or reporter modifications (NH2), so no molecular formula or weight is published here — the modified mass must come from the lot certificate of analysis. Residue composition and charge describe the peptide backbone only. Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of Urotensin I at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Cardiovascular class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
Urotensin I sits within the Cardiovascular research class (CPC reference UROT-001). Cardiovascular peptides act on GPCRs and receptor systems in vascular smooth muscle, endothelium, and cardiac myocytes — modulating vasoconstriction, natriuresis, RAAS signaling, or ionotropic responses. Effects are typically measured in isolated vessel, Langendorff heart, or receptor-transfected cell assays.</ Investigators typically incorporate Urotensin I as a reference standard, tool ligand, or substrate in the assay contexts listed above. Radioligand-binding, IP-1 / cAMP HTRF, and organ-bath tension recordings are the standard readouts.
Urotensin I (CPC catalog code UROT-001) is a synthetic cardiovascular research peptide in the cardiovascular category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use Urotensin I as a reference standard in cardiovascular workflows — for example, vascular reactivity in aortic ring and mesenteric bed preparations and renin–angiotensin–aldosterone system (raas) mechanistic studies. Human clinical evidence is not established.
No. Urotensin I is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a cardiovascular workflow, Urotensin I is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand-binding, IP-1 / cAMP HTRF, and organ-bath tension recordings are the standard readouts.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.